Curis, Inc.
CRISHealthcare|Biotechnology|US
$0.91
+0.06 (+6.65%)
Cash / Share
$2.63
Financials
Financial Snapshot
Market Cap
$1.8M
Enterprise Value
-$2.8M
Revenue (TTM)
$4.3M
Net Income (TTM)
-$21.2M
Cash & Investments
$5.6M
Net Cash
$4.6M
Free Cash Flow (TTM)
-$30.6M
Operating CF (TTM)
-$30.6M
Debt/Equity
0.22
Cash Runway & Burn Rate
Cash on Hand
$5.6M
Quarterly Burn
$7.6M
Monthly Burn
$2.5M
Est. Runway
~0.7 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $44.5M | $60.2M | $24.3M | $20.5M | $168.5M | $115.9M | $85.6M | $56.3M | $20.0M | $5.1M | $5.6M | |
| Operating Cash Flow | -$35.8M | -$48.4M | -$30.1M | -$26.2M | -$25.7M | -$37.6M | -$54.3M | -$38.4M | -$39.6M | -$27.2M | -$30.6M | |
| Free Cash Flow | -$36.1M | -$48.5M | -$30.1M | -$26.2M | -$26.4M | -$37.6M | -$54.8M | -$38.4M | -$39.6M | -$27.2M | -$30.6M | |
| Capital Expenditure | -$329.0K | -$188.0K | -$85.0K | -$41.0K | -$677.0K | $0.00 | -$416.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | -$1.4M | $64.2M | -$6.0M | $23.3M | $188.8M | -$4.2M | $867.0K | $7.6M | $3.4M | $9.8M | $23.0M |
R&D Spending
R&D (TTM)
$25.4M
R&D Intensity
589.2%
R&D Growth vs Prior
-10.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.9M | $10.4M | $10.0M | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M | $4.3M | |
| R&D Expense | $31.6M | $33.3M | $24.4M | $22.3M | $23.1M | $34.9M | $43.3M | $39.5M | $38.6M | $28.3M | $25.4M | |
| R&D % of Revenue | 419.7% | 336.9% | 234.1% | 222.9% | 212.9% | 327.6% | 425.9% | 394.1% | 353.5% | 299.2% | 589.2% | |
| SG&A | $15.6M | $25.8M | $14.8M | $11.6M | $12.1M | $17.3M | $19.6M | $18.6M | $16.8M | $14.0M | $14.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.9M | $10.4M | $10.0M | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M | $4.3M | |
| Cost of Revenue | $399.0K | $496.0K | $563.0K | $503.0K | $534.0K | $533.0K | $257.0K | $212.0K | $98.0K | $45.0K | $31.0K | |
| Gross Profit | $7.1M | $9.4M | $9.9M | $9.5M | $10.3M | $10.1M | $9.9M | $9.8M | $10.8M | $9.4M | $4.3M | |
| R&D | $31.6M | $33.3M | $24.4M | $22.3M | $23.1M | $34.9M | $43.3M | $39.5M | $38.6M | $28.3M | $25.4M | |
| SG&A | $15.6M | $25.8M | $14.8M | $11.6M | $12.1M | $17.3M | $19.6M | $18.6M | $16.8M | $14.0M | $14.8M | |
| Operating Income | -$58.0M | -$49.8M | -$29.3M | -$24.4M | -$24.9M | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$32.9M | -$36.0M | |
| Interest Expense | $2.8M | $4.0M | $3.9M | $4.8M | $5.1M | $4.5M | $4.8M | $2.0M | $615.0K | $2.2M | $0.00 | |
| Pretax Income | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M | -$21.2M | |
| Net Income | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M | -$21.2M | |
| EPS (Diluted) | -900.00 | -3575.20 | -393.40 | -387.40 | -245.80 | -198.40 | -242.80 | -179.20 | -137.60 | -11.60 | -14.22 | |
| EBITDA | -$57.4M | -$49.1M | -$28.5M | -$27.2M | -$24.7M | -$40.8M | -$51.7M | -$45.1M | -$42.6M | -$5.2M | -$21.8M | |
| Shares Out. (M) | 0.07 | 0.01 | 0.08 | 0.08 | 0.12 | 0.23 | 0.23 | 0.26 | 0.32 | 0.66 | 2.14 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.0M | $38.3M | $23.6M | $15.4M | $129.6M | $40.0M | $19.7M | $26.7M | $20.0M | $5.1M | $5.6M | |
| Short-Term Investments | $18.4M | $21.9M | $634.0K | $5.1M | $38.9M | $75.9M | $66.0M | $29.7M | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $46.9M | $64.3M | $27.1M | $25.0M | $172.8M | $122.4M | $92.1M | $60.9M | $26.4M | $6.9M | $6.7M | |
| Total Assets | $57.8M | $73.8M | $37.4M | $35.1M | $204.4M | $162.3M | $108.8M | $77.3M | $41.3M | $20.0M | $19.0M | |
| Total Current Liabilities | $8.6M | $14.1M | $6.4M | $6.5M | $10.1M | $13.4M | $10.0M | $22.0M | $19.0M | $14.1M | $13.7M | |
| Long-Term Debt | $14.9M | $35.7M | $28.6M | $0.00 | $334.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $28.5M | $49.8M | $41.9M | $69.0M | $73.7M | $71.6M | $62.3M | $57.6M | $47.3M | $14.5M | $14.3M | |
| Stockholders' Equity | $29.3M | $24.0M | -$4.5M | -$33.9M | $130.7M | $90.7M | $46.6M | $19.7M | -$6.0M | $5.5M | $4.7M | |
| Retained Earnings | -$898.9M | -$952.3M | -$984.8M | -$1.02B | -$1.05B | -$1.09B | -$1.15B | -$1.20B | -$1.24B | -$1.25B | -$1.28B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$35.8M | -$48.4M | -$30.1M | -$26.2M | -$25.7M | -$37.6M | -$54.3M | -$38.4M | -$39.6M | -$27.2M | -$30.6M | |
| Capital Expenditure | -$329.0K | -$188.0K | -$85.0K | -$41.0K | -$677.0K | $0.00 | -$416.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$36.1M | -$48.5M | -$30.1M | -$26.2M | -$26.4M | -$37.6M | -$54.8M | -$38.4M | -$39.6M | -$27.2M | -$30.6M | |
| Investing Cash Flow | $30.1M | -$3.6M | $21.4M | -$4.5M | -$49.0M | -$47.9M | $33.0M | $37.8M | $29.4M | $2.5M | $2.5M | |
| Financing Cash Flow | -$1.4M | $64.2M | -$6.0M | $23.3M | $188.8M | -$4.2M | $867.0K | $7.6M | $3.4M | $9.8M | $23.0M | |
| Issuance of Stock | $2.9M | $41.5M | $143.0K | $68.0K | $193.2M | $300.0K | $5.8M | $14.1M | $12.0M | $15.4M | $24.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$4.3M | $21.7M | -$6.1M | $23.2M | $891.0K | $0.00 | -$5.0M | $0.00 | -$8.6M | -$5.6M | -$1.6M | |
| Stock Based Comp. | $4.3M | $5.4M | $3.9M | $2.7M | $2.7M | $5.3M | $6.8M | $6.0M | $5.9M | $4.0M | $1.7M | |
| Net Change in Cash | -$7.1M | $12.3M | -$14.7M | -$8.1M | $114.0M | -$89.7M | -$20.4M | $6.9M | -$6.7M | -$14.9M | -$4.5M |
Dilution Tracker
Shares outstanding grew 441.0% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+441.0%
Stock Issuance (TTM)
$24.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.07 | 0.01 | 0.08 | 0.08 | 0.12 | 0.23 | 0.23 | 0.26 | 0.32 | 0.66 | 2.14 | |
| Change vs Prior % | — | -77.5% | 455.2% | 0.2% | 46.7% | 88.1% | 2.0% | 13.4% | 19.1% | 108.7% | 224.5% | |
| Stock Issuance | $2.9M | $41.5M | $143.0K | $68.0K | $193.2M | $300.0K | $5.8M | $14.1M | $12.0M | $15.4M | $24.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $4.3M | $5.4M | $3.9M | $2.7M | $2.7M | $5.3M | $6.8M | $6.0M | $5.9M | $4.0M | $1.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 94.7% | 95.0% | 94.6% | 95.0% | 95.1% | 95.0% | 97.5% | 97.9% | 99.1% | 99.5% | 99.3% | |
| Operating Margin % | -771.1% | -502.7% | -281.3% | -243.5% | -229.8% | -395.0% | -521.7% | -482.2% | -408.3% | -348.4% | -833.4% | |
| Net Margin % | -802.6% | -538.7% | -312.4% | -321.3% | -276.0% | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% | -490.3% | |
| EBITDA Margin % | -763.1% | -496.2% | -273.0% | -271.6% | -227.7% | -383.2% | -508.4% | -450.4% | -390.3% | -55.4% | -506.5% | |
| FCF Margin % | -480.1% | -490.4% | -289.1% | -262.4% | -243.8% | -353.3% | -538.8% | -383.5% | -362.7% | -288.1% | -709.0% | |
| ROE % | -206.4% | -222.2% | 724.5% | 94.8% | -22.9% | -50.1% | -121.7% | -241.0% | 723.4% | -138.8% | -1035.3% | |
| ROA % | -104.6% | -72.2% | -87.2% | -91.6% | -14.6% | -28.0% | -52.1% | -61.4% | -105.1% | -38.0% | -111.5% | |
| ROIC % | -107.4% | -75.9% | -77.5% | -84.8% | -12.7% | -28.1% | -53.0% | -85.4% | -188.9% | -464.7% | -567.2% | |
| R&D / Revenue % | 419.7% | 336.9% | 234.1% | 222.9% | 212.9% | 327.6% | 425.9% | 394.1% | 353.5% | 299.2% | 589.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -4.5% | 31.5% | 5.4% | -4.1% | 8.3% | -1.7% | -4.6% | -1.4% | 8.8% | -13.4% | |
| Gross Profit | -4.6% | 31.9% | 4.9% | -3.7% | 8.4% | -1.8% | -2.1% | -0.9% | 10.2% | -13.1% | |
| Operating Income | -2.8% | 14.3% | 41.1% | 17.0% | -2.2% | -68.9% | -26.0% | 8.8% | 7.8% | 26.1% | |
| Net Income | -2.4% | 11.7% | 38.9% | 1.3% | 6.9% | -51.9% | -24.7% | 16.3% | 8.5% | 82.5% | |
| EPS (Diluted) | 6.3% | -297.2% | 89.0% | 1.5% | 36.6% | 19.3% | -22.4% | 26.2% | 23.2% | 91.6% | |
| Operating Cash Flow | -19.8% | -35.0% | 37.8% | 12.8% | 1.8% | -46.2% | -44.4% | 29.3% | -2.9% | 31.2% | |
| Free Cash Flow | -20.7% | -34.3% | 37.9% | 12.9% | -0.6% | -42.4% | -45.5% | 29.8% | -2.9% | 31.2% | |
| R&D Expense | 18.3% | 5.6% | -26.8% | -8.6% | 3.4% | 51.2% | 24.1% | -8.7% | -2.4% | -26.7% | |
| SG&A Expense | 20.8% | 65.6% | -42.7% | -21.8% | 5.0% | 42.6% | 13.6% | -5.1% | -10.0% | -16.3% | |
| Total Assets | -39.2% | 27.8% | -49.4% | -6.0% | 482.1% | -20.6% | -32.9% | -29.0% | -46.6% | -51.6% | |
| Book Value / Share | -57.9% | 265.0% | -103.4% | -652.8% | 362.7% | -63.1% | -49.7% | -62.7% | -125.6% | 143.6% | |
| Debt | -17.8% | 109.2% | -14.6% | -99.5% | 4515.7% | -34.2% | -21.8% | -29.1% | 5.7% | -45.2% | |
| Diluted Shares | 7.6% | -77.5% | 455.2% | 0.2% | 46.7% | 88.1% | 2.0% | 13.4% | 19.1% | 108.7% |
Valuation
P/E (TTM)At Loss
P/S0.41
10Y Low / Med / High1.38 / 5.64 / 54.33
P/B0.41
10Y Low / Med / High0.87 / 3.05 / 13.97
EV/EBITDA0.13
EV/Revenue-0.65
10Y Low / Med / High0.21 / 4.11 / 53.51
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$2.63
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -6.84 | -0.39 | -0.70 | -1.76 | -13.33 | -9.60 | -0.91 | -1.42 | -0.44 | -1.70 | -0.06 | |
| P/S Ratio | 54.33 | 2.11 | 2.19 | 5.64 | 36.79 | 40.93 | 5.05 | 6.73 | 1.77 | 1.38 | 0.41 | |
| P/B Ratio | 13.97 | 0.87 | -5.08 | -1.66 | 3.05 | 4.81 | 1.10 | 3.43 | -3.22 | 2.38 | 0.41 | |
| EV/EBITDA | -7.01 | -0.49 | -1.22 | -1.51 | -11.21 | -9.82 | -0.69 | -0.97 | -0.05 | -1.83 | 0.13 | |
| EV/Revenue | 53.51 | 2.44 | 3.33 | 4.11 | 25.53 | 37.65 | 3.51 | 4.35 | 0.21 | 1.01 | -0.65 |
Analyst Estimates & Quality
Altman Z-Score
-98.43
Distress
Piotroski F-Score
0
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.8M | $12.3M | $5.3M |
| Net Income | -$27.2M | -$4.2M | -$65.2M |
| EPS | $-32.48 | $-5.03 | $-9.37 |
| # Analysts (EPS) | 2 | 2 | 3 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Contra Revenue | -$103.0K | -$101.0K | -$116.0K | — | — | — |
| Other Revenue | $214.0K | $1.0K | — | — | — | — |
| Royalty | $10.7M | $10.7M | — | — | — | — |
| Gross Royalty Revenue | — | — | $10.3M | $9.9M | $10.9M | — |
| Reportable Segment | — | — | — | — | — | $9.4M |